This finding suggested the possibility that GSTO1-1 inhibitors may be of value in the treatment of T2DM since IL-1β inhibitors have already been found to be effective in modulating insulin resistance [43,44]. The gene discussed is IL1B; the disease is type 2 diabetes mellitus.